Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 88186503 | 8818650 | 3 | F | 20160908 | 20121001 | 20160913 | EXP | DK-ROCHE-1137661 | ROCHE | , FERNEBRO E, PLOEN J, LINDEBJERG J, KRISTIAN A AND JAKOBSEN M. FEASIBILITY OF MOLECULAR PATIENT SELECTION IN RARE CANCERS: PHASE II STUDY OF GEMCITABINE, OXALIPLATIN AND CAPECITABINE IN KRAS MUTATED BILIARY TRACT CANCER (ABSE15620). JOURNAL OF CLINICAL ONCOLOGY 2016 MAY;34(SUPP15):-. | 0.00 | Y | 0.00000 | 20160913 | MD | DK | DK |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 88186503 | 8818650 | 1 | PS | CAPECITABINE. | CAPECITABINE | 1 | Unknown | U | 20896 | 1000 | MG/M**2 | TABLET | BID | ||||||
| 88186503 | 8818650 | 2 | SS | PANITUMUMAB | PANITUMUMAB | 1 | Intravenous (not otherwise specified) | U | 0 | 6 | MG/KG | QOW | |||||||
| 88186503 | 8818650 | 3 | SS | GEMCITABINE | GEMCITABINEGEMCITABINE HYDROCHLORIDE | 1 | Unknown | U | 0 | 1000 | MG/M**2 | QOW | |||||||
| 88186503 | 8818650 | 4 | SS | OXALIPLATIN. | OXALIPLATIN | 1 | Unknown | U | 0 | 60 | MG/M**2 | QOW |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 88186503 | 8818650 | 1 | Bile duct cancer |
| 88186503 | 8818650 | 2 | Bile duct cancer |
| 88186503 | 8818650 | 3 | Bile duct cancer |
| 88186503 | 8818650 | 4 | Bile duct cancer |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 88186503 | 8818650 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 88186503 | 8818650 | Diarrhoea | |
| 88186503 | 8818650 | Febrile neutropenia | |
| 88186503 | 8818650 | Hyperglycaemia | |
| 88186503 | 8818650 | Infection | |
| 88186503 | 8818650 | Nausea | |
| 88186503 | 8818650 | Pain | |
| 88186503 | 8818650 | Palmar-plantar erythrodysaesthesia syndrome | |
| 88186503 | 8818650 | Peripheral motor neuropathy | |
| 88186503 | 8818650 | Peripheral sensory neuropathy | |
| 88186503 | 8818650 | Rash | |
| 88186503 | 8818650 | Stomatitis | |
| 88186503 | 8818650 | Urticaria | |
| 88186503 | 8818650 | Vomiting |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |